

High Myopic Astigmatism

BY JAY BANSAL, MD; KEITH LIANG, MD; DAVID A. WALLACE, MD; AND MING WANG, MD, PhD

CASE PRESENTATION

A 36-year-old man has never been able to wear contact lenses despite numerous attempts. His manifest refraction is -14.5 +4.5 X 92 OD and -13 +3.5 X 100 OS. Pachymetry measures 579 μm OD and 578 μm OS. The slit-lamp and fundus examinations are normal, as is the patient's intraocular anatomy. He would like to discuss his refractive surgical options (Figure 1).




Figure 1. An examination with the Nidek OPD-Scan II (Nidek, Inc., Fremont, CA) reveals symmetrical with-the-rule astigmatism.

JAY BANSAL, MD

In my opinion, this patient has three viable options, all requiring an extensive discussion of their risks and benefits:

- Visian ICL or TICL (both from STAAR Surgical Company, Monrovia, CA; TICL not available in the United States) followed by LASIK
- refractive lens exchange with a toric IOL, probably followed by LASIK
- wavefront-optimized LASIK with femtosecond laser-created flap

Given his age, the patient has to decide between an intraocular (IOL or ICL) and an extraocular (LASIK) procedure. Optically, the former will yield better results but at a greater risk (eg, cataract, presbyopia, retinal detachment, infection) compared with LASIK.

After an extensive discussion, I am comfortable treating this type of patient with wavefront-optimized LASIK using a thin flap (100 μm) created with a femtosecond laser. If the patient had 6-mm pupils, I would perform the ablation with a 6-mm optical zone instead of 6.5 mm to save stromal tissue. Prior to LASIK, I would counsel this patient about alternative options for treatment (ICL and IOLs) available now and what I believe will be available in the near future. I would further advise him regarding the unlikelihood of any future enhancements after the LASIK procedure. It would also be important to counsel him regarding his increased risk of dry eyes, decreased contrast sensitivity, and halos/glare. Finally, he would need to be aware that he might still require a small prescription for spectacles/contacts for optimal visual acuity postoperatively.

The majority of patients in my practice elect to proceed with wavefront-optimized LASIK and achieve good results. Thus far, my younger patients have shown little interest in an intraocular procedure, but this may change in the near future.

KEITH LIANG, MD

Assuming the patient has an appropriate anterior chamber depth (> 3.5 mm with the IOLMaster [Carl Zeiss Meditec, Inc., Dublin, CA]) and a white-to-white measurement greater than 11.5, I would recommend a Visian ICL and laser vision correction as a two-staged procedure. His topography looks normal, with some of his astigmatism located within the lens. It is the amount of astigmatism that necessitates laser vision correction.

The first stage of the procedure would include meticulous measurements for the ICL. I would measure the white to white under a microscope and use calipers, since this information is critical to the lens' sizing. I would try to place an ICL of -10.00 D or lower. This would allow the ICL's optic to be 5.8 mm, giving the patient the largest corneal effective optical zone of 7.30 mm. Since he will require laser vision correction, any residual myopia can be addressed along with his astigmatism. I would perform a YAG peripheral iridotomy 1 to 2 weeks preoperatively and offer same-day sequential ICL surgery.

The second stage would occur 6 to 8 weeks after the ICL's implantation. The choice of wavefront-optimized or wavefront-guided LASIK/PRK would depend on the patient's optical aberrations after ICL surgery. In my experience, the Allegretto Wave Eye-Q excimer laser system (Alcon Laboratories, Inc., Fort Worth, TX) has no problem tracking eyes that have ICLs. The patient's steep keratometry readings are optimal for myopic laser correction. This second stage would allow me to correct any myopic surprises from the ICL calculations, which is why I would create the largest effective optical zone with the ICL and maintain that zone with a correction for low myopic astigmatism.

The patient's expectations would have to be addressed, because a two-staged procedure will require some patience. I would discuss his risks and benefits and allow a retinal surgeon to examine him prior to surgery. Even with the Visian TICL, this patient might require a two-staged procedure due to his high astigmatism.

DAVID A. WALLACE, MD

If the topography and pachymetry are as stated, and if in all other respects this patient would be a good candidate for the Visian ICL (endothelial cell count, anterior chamber depth, etc.), then I would be enthusiastic about two possible options. First would be bioptics with the ICL followed by LASIK, an approach I have used with modest frequency for patients exactly like this one. The second alternative, in principle, would be the Visian TICL. I now create the LASIK flap before implanting the ICL (sometimes on the day of the laser peripheral iridotomy). Two to 4 weeks after placing the ICL, I lift the flap and treat the patient's residual refractive error.

I am in the habit of imaging the anterior and posterior surfaces of all laser refractive candidates. I would therefore obtain a study with either the Orbscan topographer (Bausch + Lomb, Rochester, NY) or the Pentacam Comprehensive Eye Scanner (Oculus, Inc., Lynnwood, WA) to complete his workup. For surgical planning, I would prefer to use a high-frequency ultrasonic instrument to determine a sulcus-to-sulcus measurement for ICL sizing. Sizing based on any white-to-white measurement does not always correlate perfectly with the sulcus-to-sulcus measurement.

MING WANG, MD, PhD

The patient has normal corneal thickness and corneal topography. Assuming good ocular health, a stable refraction, and good BCVA, the patient has two options if he is motivated and understands their risks and potential complications. The first is refractive lens exchange with a limbal relaxing incision (LRI) and the placement of a toric IOL. The second is implantation of the Visian ICL, with or without an LRI, followed by a planned LASIK/PRK procedure.

Typically, a small number of my patients choose refractive lens exchange. I would discuss with this patient the risks, including a slightly increased chance of retinal detachment due to his high myopia. If he elected to proceed, I would ensure that the patient understood that he might subsequently require a keratorefractive procedure to address his astigmatism. I would also explain that the best surgical endpoint would be plano for the dominant eye and -1.25 D for the nondominant eye, and I would conduct a contact lens monovision trial if needed. In terms of surgery, I would extract the crystalline lens, create an LRI, and implant a toric IOL.

If the patient chose instead to receive a phakic IOL, I would explain that the Visian TICL may become available late this year or next year and suggest that waiting would be an excellent option. If he wished to proceed immediately with surgery and he were strongly motivated to undergo ICL surgery now, I would determine his candidacy for the lens (in terms of anterior chamber depth, etc.). I would also discuss with him the risks of ICL surgery, which include the need for subsequent keratorefractive surgery to correct residual spherical error and astigmatism in addition to the routine risks of endophthalmitis, cataract, glaucoma, etc.

The astigmatic treatment plan and ICL power calculation depend on whether or not the surgeon performs an LRI at the time of the ICL's implantation. I generally do, which reduces the amount of astigma-

NEVANAC® (nepafenac ophthalmic suspension) 0.1%, topical ophthalmic
 Initial U.S. Approval: 2005

Revised: 9/2007

tism requiring subsequent correction by LASIK/PRK and thus increases the laser procedure's precision and accuracy.

In this case, I would perform an LRI to debulk the cylinder during the ICL surgery and target a postoperative spherical equivalence that was either equal to zero (eg, -2.25 +4.50 cylinder and -1.75 +3.50 cylinder) or a bit more minus (eg, -4.50 +4.50 cylinder and -3.50 +3.50 cylinder). The reason is that spherical values of opposite signs tend to cover up the cylinder. The efficacy of refractive surgery for such eyes (where the magnitude of the sphere is at least equal to that of the cylinder) is much better than for mixed astigmatism, where the magnitude of the cylinder is much larger than that of the sphere. It is important to keep in mind that the LRI does not change spherical equivalence. ■

Section Editor Stephen Coleman, MD, is the director of Coleman Vision in Albuquerque, New Mexico. Parag A. Majmudar, MD, is an associate professor, Cornea Service, Rush University Medical Center, Chicago Cornea Consultants, Ltd. Karl G. Stonecipher, MD, is the director of refractive surgery at TLC in Greensboro, North Carolina. Dr. Stonecipher may be reached at (336) 288-8523; stonenc@aol.com.

Jay Bansal, MD, is the medical director of LaserVue Eye Center in Santa Rosa, California. He acknowledged no financial interest in the products or company he mentioned. Dr. Bansal may be reached at (707) 522-6200; bansal@laservue.com.



Keith Liang, MD, is the medical director at Center for Sight in Sacramento, California. He acknowledged no financial interest in the products or companies he mentioned. Dr. Liang may be reached at (916) 446-2020; kliang@liangvision.com.



David A. Wallace, MD, is the medical director for LA Sight in Los Angeles. He acknowledged no financial interest in the products or companies he mentioned. Dr. Wallace may be reached at (310) 828-2020; drdave@la-sight.com.



Ming Wang, MD, PhD, is the international president of Shanghai Aier Eye Hospital, a clinical associate professor of ophthalmology at the University of Tennessee, and the director of the Wang Vision Cataract and LASIK Center in Nashville, Tennessee. He acknowledged no financial interest in the products or companies he mentioned. Dr. Wang may be reached at (615) 321-8881.



BRIEF SUMMARY

1 INDICATIONS AND USAGE

NEVANAC® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

One drop of NEVANAC® should be applied to the affected eye(s) three-times-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.

2.2 Use with Other Topical Ophthalmic Medications

NEVANAC® may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alp ha-agonists, cycloplegics, and mydriatics.

3 DOSAGE FORMS AND STRENGTHS

Sterile ophthalmic suspension: 0.1%

3 mL in a 4 mL bottle

4 CONTRAINDICATIONS

NEVANAC® is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs.

5 WARNINGS AND PRECAUTIONS

5.1 Increased Bleeding Time

With some nonsteroidal anti-inflammatory drugs including NEVANAC®, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

It is recommended that NEVANAC® ophthalmic suspension be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

5.2 Delayed Healing

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) including NEVANAC®, may slow or delay healing.

Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

5.3 Corneal Effects

Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs including NEVANAC® and should be closely monitored for corneal health.

Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post surgery may increase patient risk and severity of corneal adverse events.

5.4 Contact Lens Wear

NEVANAC® should not be administered while using contact lenses.

6 ADVERSE REACTIONS

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

6.1 Ocular Adverse Reactions

The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These events occurred in approximately 5 to 10% of patients.

Other ocular adverse reactions occurring at an incidence of approximately 1 to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing and vitreous detachment.

Some of these events may be the consequence of the cataract surgical procedure.

6.2 Non-Ocular Adverse Reactions

Non-ocular adverse reactions reported at an incidence of 1 to 4% included headache, hypertension, nausea/vomiting, and sinusitis.

See full prescribing information for NEVANAC®.



ALCON LABORATORIES, INC.
 Fort Worth, Texas 76134 USA